Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE): A Registry for Characterizing Anaemia Management and Outcomes in Oncology Patients

Author： Larholt Kay  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.28, Iss.3, 2008-01, pp. : 159-167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erythropoiesis-Stimulating Agents in Oncology

By Glaspy John A.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 6, 2008-07 ,pp. : 565-575

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents

By Mei Sheng Duh  

PharmacoEconomics, Vol. 26, Iss. 2, 2008-01 ,pp. : 99-120

Adis International

Access to resources Recommend Favorite

Erythropoiesis-stimulating agents in patients with cancer: update on safety issues

By Pirker Robert  

Expert Opinion on Drug Safety, Vol. 8, Iss. 5, 2009-09 ,pp. : 515-522

Informa Healthcare

Access to resources Recommend Favorite

Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis

By Escudero-Vilaplana Vicente  

International Journal of Clinical Pharmacy, Vol. 35, Iss. 3, 2013-06 ,pp. : 463-468

Springer Publishing Company

Access to resources Recommend Favorite

Differentiating Factors Between Erythropoiesis-Stimulating Agents: A Guide to Selection for Anaemia of Chronic Kidney Disease

By Deicher R.   Hörl W.H.  

Drugs, Vol. 64, Iss. 5, 2004-01 ,pp. : 499-509

Adis International

Access to resources Recommend Favorite